Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Grants Stock Options

MarketWire Canada August 31, 2017

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

Marketwired August 16, 2017

Acasti Pharma Reports First Quarter FY 2018 Financial Results

MarketWire Canada August 14, 2017

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures

MarketWire Canada July 28, 2017

CORRECTION: Acasti Pharma Grants Stock Options

Marketwired June 16, 2017

Acasti Pharma Grants Stock Options

MarketWire Canada June 14, 2017

Acasti Pharma To Present at Upcoming International Industry Conferences

MarketWire Canada June 12, 2017

Acasti Pharma Reports Fourth Quarter and Full-Year 2017 Financial Results

Marketwired June 6, 2017

Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with New Continuous Manufacturing Process

MarketWire Canada May 31, 2017

Acasti Pharma Presents CaPre Clinical Data at National Lipid Association Scientific Sessions

MarketWire Canada May 18, 2017

Acasti Granted Additional Composition & Use Patents in Taiwan and Australia; Safeguards Valuable Market Expansion Opportunities

MarketWire Canada April 24, 2017

Acasti Pharma to Present CaPre Omega-3 Bridging Study Results at National Lipid Association Scientific Sessions

MarketWire Canada April 12, 2017

Mid-Afternoon Market Update: Dow Rises Over 50 Points; Exfo Shares Tumble

Benzinga.com  March 30, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 30, 2017

Acasti Pharma Provides Update On CaPre Phase 3 Development Program

Marketwired March 30, 2017

Acasti Pharma Forms Scientific Advisory Board and Appoints Two Leading Cardiovascular Disease Experts

Marketwired March 8, 2017

Acasti Pharma Grants Incentive Stock and Options

MarketWire Canada February 24, 2017

Acasti Pharma Announces Closings of Concurrent Public Offering of Units and Private Placement of Convertible Debentures and Warrants

MarketWire Canada February 21, 2017

Acasti Pharma Announces Pricing for its Public Offering of Units

Marketwired February 10, 2017

Acasti Pharma Announces Proposed Private Placement of Convertible Debentures and Amended Proposed Offering of Units

Marketwired February 2, 2017